Mayne Pharma Group Limited (ASX: MYX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mayne Pharma Group Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mayne Pharma Group Limited (ASX: MYX)
Latest News
Share Market News
ASX 200 down 0.1%: Carsales update impresses, a2 Milk surges higher
Share Market News
The ASX winners and losers from the latest S&P index shake-up
Share Market News
These 5 ASX shares were last week's worst performers
Share Market News
These were the worst performing shares on the ASX 200 last week
Share Market News
ASX 200 down 2.2%: Westpac tumbles, TPG reveals special dividend plans
Share Market News
S&P quarterly rebalance: A2 Milk added to ASX 50 & NEXTDC in the ASX 100
Share Gainers
The best performing ASX 200 stock today may have more room to climb
Share Market News
Fund managers have been buying these ASX shares
Share Market News
ASX 200 up 0.35%, CBA gives Q3 update
Share Market News
Why these ASX shares are well placed to outperform into next month
⏸️ TMF AMP
ASX 200 flat: NAB raises $3bn and Westpac reveals $1.6bn coronavirus impacts
Share Market News
ASX 200 weekly wrap: Negative oil price breaks ASX's winning streak
Frequently Asked Questions
-
Mayne Pharma made a fully franked cash payment to shareholders in January 2023. Prior to that, the company’s last dividend payout was in 2011.
-
Mayne Pharma Group Ltd listed on the ASX on 29 June 2007.
MYX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mayne Pharma Group Limited
Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company focused on commercialising branded and generic pharmaceutical products. Its South Australian manufacturing base produces a portfolio of oral and topical products including tablets, powders, capsules, liquids, and creams.
Mayne Pharma performs limited research and development, typically acquiring off-patent or tail-end pharmaceutical brands. The company also has a contract manufacturing segment and advertises its services in assisting other drug developers in getting their products to market. The Group earns more than 90% of its revenue from the US market.
